Can Real-World data uncover hidden risks of the Alzheimer's drug LEQEMBI?

NCT ID NCT07762092

Not yet recruiting Knowledge-focused Sponsor: Eisai Limited Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This registry study follows 400 Alzheimer's patients in Canada who are prescribed LEQEMBI, a medication for the disease. The goal is to track the frequency and severity of known side effects, such as brain swelling (ARIA-E), microbleeds (ARIA-H), and larger brain hemorrhages, during routine clinical care. It also looks for any new or unexpected long-term safety issues and how the drug is used in practice. By observing patients in real-world settings, the study aims to better understand the drug's safety profile beyond clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LEQEMBI (lecanemab), an Alzheimer's disease medication
What this could lead to: If successful, this study could provide a clearer picture of LEQEMBI's real-world safety, helping doctors manage risks like brain swelling or bleeding in Alzheimer's patients.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove cause and effect. It may also not capture all rare or long-term side effects due to its design and limited follow-up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMERS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMERS DISEASE

Contacts and locations

Locations

Bruyère Institute

Ottawa, Ontario, Canada
CHU de Québec-Université Laval Research Center

Québec, Quebec, Canada
Kawartha Center

Peterborough, Ontario, Canada
McGill University, Douglas Mental Health

Montreal, Quebec, Canada
Parkwood Hospital - London

London, Ontario, Canada
Sunnybrook Hospital

Toronto, Ontario, Canada
Toronto Memory Program

Toronto, Ontario, Canada
Toronto Western Hospital

Toronto, Ontario, Canada
Trillium Hospital

Mississauga, Ontario, Canada
UBC Victoria - Neil and Susan Manning Cognitive Health Initiative

Victoria, British Columbia, Canada
University of British Columbia - CARD

Vancouver, British Columbia, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.